We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Most hand-held injectors today are designed for standard drug containers, such as prefilled syringes or cartridges. The primary markets include treatments for chronic conditions such as diabetes and hormone deficiencies where repeat injections are necessary and are administered by the patient or a caregiver.
Typically, a device helps to simplify the patient injection experience, although many self-injections are still given with a basic prefilled syringe, potentially incorporating a needle-safety system or ergonomic accessories to improve an impaired patient’s ability to deliver an injection, particularly when it may be very viscous. Various sources suggest the market for prefilled syringes is getting close to three billion units per year, with a steady growth rate, although hand-held devices are used in only a portion of cases.
Growth continues in devices for insulin delivery, driven by continuing diagnosis and increased use of devices such as pens.
A key trend is an increased need for delivery systems capable of containing and delivering injectable doses of greater than 1mL, either in a single-dose rapid shot, or slowly over a longer period of time. This trend is driven by the challenges of next-generation biologics, including increased concentrations and higher viscosities. There is also a trend toward reduced dosing frequency, which may help improve patient comfort and compliance.
West offers a variety of self-injection technologies, including the SelfDoseTM, SmartDose® and ConfiDose® injector platform technologies. For more information click here.
SelfDoseTM, SmartDose® and ConfiDose® are trademarks or registered trademarks of West Pharmaceutical Services, Inc., or its affiliated companies, in the United States and other jurisdictions.
West seeks partners for its injector technology platforms. These platforms are intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.
West works by the side of our health care partners to understand patient needs and provide integrated delivery systems that optimize the effectiveness of drug delivery while enhancing the patient experience. Creative business models will ensure effective collaboration, either by leveraging West’s proprietary technologies or partnering with individual customers through the development process to apply West’s design, engineering and manufacturing skills to create customer-specific solutions.
In a previous <a href="/blog/2012/may/lifecycle-planning"><span style="text-decoration: underline;">post</span></a>, my colleague Fran DeGrazio discussed lifecycle planning and the use of a single material for packaging components from development through commercialization. There has been a great deal of innovation around drug container materials. Although glass has been the traditional material of choice for drug containment, it has significant limitations including breakage, glass particulate, visual quality and functional performance.
Standing front and foremost in biologic drug formulation is the optimization of safety and efficacy while ensuring quality and stability during manufacturing. Biologic manufacturing subjects the formulation to different stresses and conditions that may compromise quality and stability. Recently, the requirement for the development of subcutaneous formulations for high dose drugs, such as monoclonal antibodies, at high protein concentrations has created additional challenges, including degradation.
As the adoption and acceptance of self-administered therapies grows, patients are spending less time with physicians and are playing a greater role in the delivery and management of their treatments. With the growing demand for extended-release and high-concentration formulations, more drug delivery systems choices are now available to differentiate drug products in a crowded market. Patient preferences can drive the selection of self-injection systems for a drug therapy. Selecting a system that patients prefer can, simplify use and increase compliance with the dosage regimen.
The drive for high-quality packaging has helped manufacturers focus on increasing consistency of performance in devices such as auto-injector and patch injection systems. In addition, there is an increased focus on providing drug delivery systems that are easy to use. A consistent quality of components can help to improve performance and ensure delivery in the home environment, while user-centric systems can help assist with compliance.
English
Chinese
